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Purpose: To compare the effects of artificial tears (ATs) in wearers of biweekly replacement
silicone hydrogel contact lenses (BW-Ws) and wearers of daily disposable contact lenses
(DD-Ws) of the same material.
Materials and Methods: The aqueous-supplementing ATs, OPTOyalA and OPTOidro,
were assigned to be used for 2 weeks to healthy and young subjects: 1) 20 (8 and 12,
respectively) BW-Ws wearing silicone hydrogel somofilcon A CLs (Clariti Elite), 2) 18
(9 and 9, respectively) DD-Ws wearing silicone hydrogel somofilcon A CLs (Clarity 1 Day),
and 3) a control group of 33 (16 and 17, respectively) N-Ws. Ocular symptoms and comfort,
tear volume and stability, and ocular surface condition were assessed by Ocular Surface
Disease Index (OSDI), 5-Item Dry Eye Questionnaire (DEQ5), tear meniscus height (TMH),
non-invasive tear break-up time (NIBUT), and evaluation of ocular redness (OR). The
assessment was performed before and after 15 days of use of the ATs in the 3 groups (BW-
Ws, DD-Ws, and N-Ws).
Results: No clear significant difference was noted in symptoms and signs between
OPTOyalA and OPTOidro irrespectively of the group of people studied. ATs use for
15 days produced a significant improvement in DEQ5 and OR in DD-Ws (Δ=−34%,
p=0.006; Δ=−23%, p<0.001) and in N-Ws (Δ=−21%, p=0.001; Δ=−10%, p=0.006) but not
in BW-Ws (Δ=−5%, p=0.072; Δ=−2%, p=0.257). No significant change was noted for TMH.
Conclusion: In young and healthy subjects, the aqueous-supplementing effect of the ATs
under consideration is more a rinsing and tear replacem ent effect than an increase in tear
volume, and it produces an improvement of the eye redness and ocular symptoms. Contact
lens wear influenced the effectiveness of ATs in a way which is correlated with the CL
replacement schedule.
Keywords: artificial tears, contact lenses, somofilcon A
Introduction
In the first approximation, the tear film is typically described by a mixed inner
aqueous-mucins layer with an outer lipid layer.1 A stable and healthy tear film
provides a protective layer, which guarantees good eye comfort and vision thanks to
the hydration and nutrition of the cornea and conjunctiva, the protection of the
ocular surface from dust, dirt particles, and foreign bodies, and the maintenance of
corneal transparency.1–3 When the quality or quantity of tears are compromised due
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to some dysfunctions, tear film instability and dry eye
symptoms may occur.4–9 It has been indicated that the
prevalence of dry eye ranges from approximately 5% to
50% when the diagnosis is based on symptoms with or
without signs.8 However, when the diagnosis is based
primarily on signs, studies generally reported higher and
more variable rates of disease, up to 75%.8
Artificial tears (ATs) are tear substitutes, which are
available over-the-counter and are often used as the first
line of treatment in order to supplement a deficient natural
tear film to treat dryness and irritation.10,11 For a sustained
therapeutic effect, these formulations should remain on the
ocular surface for a sufficiently long time, but newly
secreted tears can dilute and wash away active agents, and
blinking can remove instilled tear substitutes, which flow
through the main excretory ducts.10–13 Their relative short
retention time leads to high frequency of instillation.
Generally speaking, there are two major types of ATs, one
that supplements the aqueous part of the tear and the other
that supplements the lipid part.10 Aqueous-supplementing
ATs are expected to provide lubrication and an enhancement
of viscosity.10 Among them, there are simple saline-based
solutions and other ATs containing natural and synthetic
polymers.10 Ingredients are typically polyacrylic acid, car-
boxymethyl cellulose (CMC), dextran, hyaluronic acid
(HA), hydroxypropyl guar, hydroxypropyl methylcellulose
(HPMC), polyvinyl alcohol (PVA), polyvinylpyrrolidone
(PVP), and polyethylene glycol.10 These ingredients pro-
long the time that the ATs stay on the eye. Specifically, HA,
a long polysaccharide with a high molecular weight which
is present in connective tissue and in other parts of the
human body,14,15 is a component of many ATs in the form
of its sodium salt (sodium hyaluronate). Due to its viscos-
ity-enhancing properties, some manufacturers also add
sodium hyaluronate directly in the solutions of the CL
blister to improve the comfort after CL insertion.15–18
Lipid-supplementing ATs were introduced because a lipid
deficit can cause a quicker evaporation of the tears leading
to a condition of dry eye.10 These are typically emulsions
where lipid droplets are suspended, such as polar phospho-
lipid, dimyristoyl-phosphatidyl-glycerol (DMPG), propy-
lene glycol.19,20
In the literature, several studies on the clinical effects
of ATs and on the comparison between them are
reported.13,21–29 Some of these studies concern the reten-
tion time on the ocular surface and both symptoms and
signs in patients with dry eye. In rat and rabbit animal
models of dry eye, sodium hyaluronate was reported to
show a significantly longer retention time than other ATs,
including carboxymethylcellulose and hydroxypropyl
methylcellulose.13 Aragona et al found that sodium hya-
luronate is also able to improve the conjunctival epithelial
cell abnormalities of the ocular surface.22
Recent studies found that more than half of the CL
wearers suffer from dry eye, a much higher percentage
than found in the general population matched for age.8,23
In CL wearers, a stable tear film is a requirement because it
keeps the CL hydrated, ensures an adequate oxygen trans-
mission, and reduces the chances of bacterial contamination
of the CL.30–32 However, the interaction between tear film
and CLs is certainly affected by the frequency of replace-
ment of CLs for the different building up of deposits on the
lens surface which is potentially reduced by the use of daily
disposable CLs. Moreover, daily disposable CLs require the
least amount of upkeep and have the advantage of reducing
complications associated with case contamination and use
of care products.33–41 However, the costs are typically
higher and throwing the CLs every day means increased
waste disposal due to the CL itself and its packaging.
The present work concerns CL wear combined with the
use of ATs. The question that gave rise to this work was
to investigate whether the efficacy of an aqueous-
supplementing AT in symptoms and ocular signs is different
in wearers of daily disposable CLS (DD-Ws), in wearers of
CLs of the same material with lower frequency replacement,
and in non-wearers (N-Ws).
Materials and Methods
Artificial Tears
OPTOyalA and OPTOidro ATs (OPTOX, Italy) were used
in this work in single-dose format (0.35 mL each). They are
both isotonic saline solutions buffered to pH 7.2. In addi-
tion, OPTOyalA contains, as declared by the manufacturer,
sodium salt of hyaluronic acid (1.5 mg/mL), L-proline
(0.752 mg/mL), L-glycine (1 mg/mL), L-lysine hydrochlor-
ide (0.14 mg/mL), and L-leucine (0.108 mg/mL).
The osmolarity of the ATs was measured by the
TearLab™ osmolarity system (Tear Lab, California,
USA). The measured values (mean ± standard deviation
of five repetitions) were 292±2 Osm/L (OPTOyalA) and
290±2 Osm/L (OPTOidro).
The refractive index (mean ± standard deviation of five
repetitions) was measured (OPTOyalA: 1.33584±0.00004;
OPTOidro: 1.33543±0.00004) by a digital refractometer
Atago RX3000α for liquids (Atago, Japan).
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The determination of relative viscosity was carried out
at 18°C by using a homemade capillary viscometer. The
relative viscosity (ηr ¼ η=η0) was evaluated by correlating
two measurements: one performed on the AT (η) and the
other on an isotonic solution containing 0.9% sodium
chloride without preservatives (Alcon Vision Care, USA)
used as reference (η0). The measured value of ηr was 3.26
±0.01 for OPTOyalA and 1.04 ± 0.01 for OPTOidro (mean
± standard deviation of five repetitions).
Contact Lenses
Either daily disposable or 1-month manufacturer-
recommended replacement CLs of the same material
were included in the study. The 1-month manufacturer-
recommended replacement CLs were actually used for
2 weeks (BW-W group) in the study. Some of their proper-
ties are shown in Table 1. Daily disposable CLs (somofil-
con A Clarity 1 Day, Cooper Vision, USA) were used by
18 wearers (DD-Ws), as described below, while 1-month
replacement CLs (somofilcon A Clariti Elite, Cooper
Vision, USA) for daily use were worn by 20 wearers (BW-
Ws). The Refine One Step hydrogen peroxide solution
(Cooper Vision, USA) was also given to BW-Ws for the
overnight CL storage.
Participants and Study Design
The study was conducted according to the tenets of the
Declaration of Helsinki. Before being enrolled in the study
each subject expressed his/her written informed consent and
gave the researchers permission to collect and treat personal
and optometric data. The subjects took part in the project for
free. The Optics and Optometry Board of the University of
Milano Bicocca granted approval for the study (June 2018).
A scheme of the study design is shown in Figure 1.
During the recruitment phase, the inclusion criteria
were the absence of any known ocular and systemic
pathologies, not having used any eye drops (ATs included)
in the week before the study began, and, only for non-
wearers, never having worn CLs.
Thirty-three N-Ws were recruited and, on the first day
(Figure 1), a standard protocol was carried out (described
in the clinical assessment section below) to assess ocular
symptoms and the condition of tear film and ocular sur-
face. These subjects were randomly assigned to one of two
N-W subgroups based on the dispensed ATs (Figure 1 and
Table 2): 16 subjects out of 33 were assigned at the
OPTOyalA subgroup and 17 were assigned at the
OPTOidro subgroup. All 33 subjects received an adequate
number of packages of ATs in single-dose formats
(0.35 mL each) to allow using the assigned AT for 2
weeks of use (3 times a day at times chosen by each
subject, each application separated from the previous one
by at least 3 hours). The clinical assessment was repeated
on the fifteenth day (Figure 1).
Thirty-eight CL wearers (habitual or occasional wear-
ers of CLs of different materials and different replacement
modality) were recruited and randomly assigned to one of
the two groups: 18 subjects in the DD-W group and
20 subjects in the BW-W group (Figure 1). All subjects
received a proper number of the assigned CLs (thirty
blisters of daily disposable CLs and a pair of 1-month
replacement CLs of the appropriate optical power) to be
used on a daily wear basis (8±1 hours a day) for 2 weeks
without any AT. For the BW-W group, subjects were also
provided with a package of hydrogen peroxide solution
(Refine One Step, Cooper Vision, USA) as the CL care
system. For CL wearers, the experimental phase of this
study began at the end of these 2 weeks of preliminary
wear (as shown by a dashed box in Figure 1). On the
first day of the experimental phase, the standard protocol
(clinical assessment) to assess symptoms, tear film, and
ocular surface was carried out. Each group (DD-Ws and
BW-Ws) was further divided into two subgroups depend-
ing on the randomly assigned AT (Figure 1 and Table 2).
Nine out of 18 DD-Ws were included in the DD-W sub-
group using OPTOyalA, the other 9 DD-Ws were included
in the DD-W subgroup using OPTOidro. Eight out of
20 BW-Ws were included in the BW-W subgroup using
OPTOyalA, and the other 12 BW-Ws were included in the
Table 1 Contact Lenses
Material Somofilcon A Somofilcon A
Brand Clarity 1 Day Clariti Elite
Manufacturer Cooper Vision,
USA
Cooper Vision, USA
Replacement Daily Monthly (worn for two
weeks in this work)
Equilibrium water
content (%)
56 56
−3.00D central
thickness (mm)
0.07 0.07
Elastic modulus
(MPa)
0.50 0.50
Note: Properties of the contact lenses used in this work.
Dovepress Tavazzi et al
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OPTOidro subgroup. New CLs were then provided: a pair
of 1-month replacement CLs were dispensed to the group
of BW-Ws to be used in the following 2 weeks together
with the assigned ATs and 30 blisters of daily disposable
CLs were dispensed to the DD-Ws. After 2 weeks of wear,
the clinical assessment was repeated (Figure 1). CLs were
worn for 8±1 hours every day. ATs were instilled three
times a day with the CL in-situ, at times chosen by each
subject, each application separated from the previous one
by at least 3 hours.
All participants of the three groups (N-Ws, DD-Ws,
and BW-Ws) completed the project and stated that they
had followed the instructions provided. The refractive
error (spherical equivalent) of the study participants was
included in the range between −12.00 D and +2.00
D (mean = 3.39 D, std dev = 2.67 D).
Clinical Assessment
The clinical assessment consisted of the ocular surface
symptoms measurement gathered through the use of two
Figure 1 Scheme of the study design showing the recruitment of non-wearers (N-Ws) and wearers of contact lenses (CLs), either daily disposable contact lenses (DD-Ws)
or biweekly replacement contact lenses (BW-Ws), and the 15-day experimental phase in which artificial tears (ATs) were used.
Table 2 Groups and Subgroups
Group Subgroup Nmales Nfemales Nsubgroup Ngroup Age (years)
Mean Std Dev
N-W OPTOyalA 10 6 16 33 25.1 3.2
OPTOidro 7 10 17 23.2 2.7
DD-W OPTOyalA 3 6 9 18 22.0 1.3
OPTOidro 5 4 9 22.9 1.1
BW-W OPTOyalA 4 4 8 20 23.5 1.2
OPTOidro 4 8 12 25.0 2.3
Notes: Number of males/females, total number of subjects (Nsubgroup), mean age, and standard deviation of the age for each subgroup (OPTOyalA and OPTOidro) of the
three groups (non-wearers, wearers of daily disposable contact lenses, wearers of biweekly replacement contact lenses).
Abbreviations: Nmales, number of males; Nfemales, number of females; Nsubgroup, total number of subjects of the subgroup; Ngroup, total number of subjects of the group;
N-W, non-wearers; DD-W, wearers of daily disposable contact lenses; BW-W, wearers of biweekly replacement contact lenses.
Tavazzi et al Dovepress
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standardized questionnaire and in three objective measure-
ments of tear film and ocular surface: tear meniscus height
(TMH), non-invasive tear break-up time (NIBUT), and
ocular redness evaluation (OR).
The two questionnaires to evaluate ocular surface symp-
toms were the Ocular Surface Disease Index (OSDI)42 and
the 5-Item Dry Eye Questionnaire (DEQ-5).43
The TMH measurement, performed to achieve
a measure of tear volume,44 was carried by a two-step
procedure as described by the Dry Eye Report (CSO,
Firenze, Italy) integrated in the software platform called
Phoenix (CSO, Firenze, Italy): a digital image of the
inferior tear meniscus was firstly acquired, then the height
of the meniscus in a central position (just under the virtual
extension of the vertical axes of the cornea) was measured
by the digital ruler device of the software. The evaluation
was repeated three times and the mean value was taken
into consideration.
The non-invasive tear break-up time (NIBUT) was
performed using the Dry Eye Report (DER) (CSO,
Firenze, Italy). The software allowed to detect the first
tear break up through an automatic algorithm. The mea-
surement was repeated three times and the mean value was
taken into consideration.
OR was measured because considered the most com-
mon clinical sign that is suggestive of ocular surface
inflammation.44 A snapshot of temporal bulbar conjunctiva
was taken by the Dry Eye Report (CSO, Firenze, Italy) and
the bulbar ocular redness. All images were saved as
masked codes and OR severity was subsequently deter-
mined by comparison with the templates of Efron Grading
scales.45
In the clinical assessment sequence, each subject was
firstly requested to complete the two questionnaires then
the objective assessment was carried out in the following
order: TMH, NIBUT, and OR. The two repeated clinical
assessments were carried out at the same time in the
morning (with a tolerance of 1 hour) in order to minimize
possible effect of diurnal variation.46 For each subject,
only the data of the right eye were analyzed.
Statistical Analysis
Descriptive statistics (mean, standard deviation SD) was
produced for the measurements (OSDI, DEQ5, TMH,
NIBUT, OR) collected on the first day and on the fifteen-
th day of the experimental phase. For each subject, the
percentage change (Δ) of each variable was also calculated
as the difference between the values measured on the
fifteenth day and on the first day divided by the value of
the first day. Mean and SD were also calculated for these
percentage changes.
For each group separately (N-Ws, DD-Ws, BW-Ws),
a preliminary analysis was performed to compare the
results of the two subgroups based on the type of AT
(OPTOyalA or OPTOidro). Due to the small number of
subjects, non-parametric statistics were used (unpaired
Mann–Whitney, level of significance: p-value < 0.05).
The subsequent analyses concerned (i) the three groups
consisting of all N-Ws, all DD-Ws, and all BW-Ws
regardless of the assigned AT, (ii) the three groups con-
sisting of N-Ws using OPTOyalA, DD-Ws using
OPTOyalA, and BW-Ws using OPTOyalA, and finally
(iii) the three groups consisting of N-Ws using
OPTOidro, DD-Ws using OPTOidro, and BW-Ws using
OPTOidro. The comparison between the results obtained
in each group on the first day and on the fifteenth day was
performed by the non-parametric Wilcoxon test (level of
significance: p-value < 0.05).
Results and Discussion
For each group separately (N-Ws, DD-Ws, BW-Ws) and
for each subgroup (OPTOidro and OPTOyalA), Figure 2
shows the mean values measured on the 1st and 15th days.
The values are also tabulated in Table 3, together with the
mean percentage variations (Δ) for each variable, which
allow to probe the effect of the ATs without the subjects’
initial individual variability influencing the data analysis.
A preliminary analysis was carried out to compare the
results of the two subgroups. The p-values obtained by
unpaired comparison between the Δ values of the two
subgroups (OPTOyalA vs OPTOidro) are also tabulated
in Table 3 for each group. Only for the TMH of BW-Ws
(1 comparison out of 15), the effect of the two ATs was
noted to be different (p=0.041 in Table 3). However,
neither of the two corresponding TMH Δ values showed
a significant variation between the 1st and the 15th day
(+14% in the case of OPTOyalA showing p=0.263 and
−12% in the case of OPTOidro showing p=0.195). This
makes the difference between the two ATs in the unpaired
comparison of little clinical significance. No significant
differences were noted in the unpaired comparison
between the two subgroups (OPTOyalA vs OPTOidro,
p>0.05) for all other variables. Looking carefully at
Table 3, some other apparent discrepancies concern OR
of N-Ws, DEQ5 of DD-Ws, and NIBUT of BW-Ws.
Concerning the OR of N-Ws, the variation between the
Dovepress Tavazzi et al
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1st and the 15th day was significant only for the
OPTOyalA subgroup and for the whole group of 33 sub-
jects. Although it was not significant for the OPTOidro
subgroup (p=0.130), the overall result of all the 33 N-Ws
well represents this group. Indeed, all three OR Δ values
of N-Ws are negative (−10%, −12%, −8%) and the
unpaired comparison between OPTOyalA and OPTOidro
did not result in a significant difference (p=0.416). The
scenario is similar for the DEQ5 of DD-Ws. All three
DEQ5 Δ values of DD-Ws are negative (−34%, −44%,
−24%) and the comparison between OPTOyalA and
OPTOidro did not result in a significant difference
(p=0.352). Although the variation between the 1st and
the 15th day was not significant for the OPTOidro sub-
group (p=0.175), the overall result of all the 18 DD-Ws
well represents the DD-W group. Finally, concerning the
NIBUT of BW-Ws, the variation between the 1st and the
15th day was significant only for the OPTOidro subgroup
and for the whole group of 33 subjects. Although it was
not significant for the OPTOyalA subgroup (p=0.799), the
overall result of all the 20 BW-Ws well represents this
group. Indeed, all three Δ values are positive (+35%,
+29%, +40%) and the comparison between OPTOyalA
and OPTOidro did not result in a significant difference
(p=0.160). In all the other 11 out of 15 cases of Table 3,
the variations after 15 days of the OPTOyalA subgroup
only, of the OPTOidro subgroup only, and of the group as
a whole showed the same type of behavior and the same
statistical evidence. Based on these considerations, the
subsequent analyses concerned the three groups consisting
of 33 N-Ws, 18 DD-Ws, and 20 BW-Ws regardless of the
assigned AT.
Even if the purpose of this work was the comparison
between the 1st and the 15th day, a first comment concerns
the data obtained on the 1st day in the three groups. The
results are compatible with the expected results for young
and healthy subjects. The most interesting parameter was
found to be the OR because a statistically greater average
value was found for the 18 DD-Ws on the 1st day than for
the 33 N-Ws (1.7±0.3 vs 1.0±0.6), as well as for the
20 BW-Ws compared to N-Ws (2.0±0.6 vs 1.0±0.6).
Even if it is not reported in Table 3, an unpaired Mann–
Whitney test between the data taken on the 1st day pro-
vided p<0.001 in both of these comparisons. After
15 days, a significant OR improvement was found in
N-Ws (−10%) and DD-Ws (−23%). From a clinical point
Figure 2 Mean data measured on the 1st and 15th days for the two ATs separately.
Abbreviations: N-Ws, non-wearers; DD-Ws, wearers of daily disposable contact
lenses; BW-Ws, wearers of biweekly replacement contact lenses; OSDI, Ocular
Surface Disease Index; DEQ5, 5-Item Dry Eye Questionnaire; TMH, tear meniscus
height; NIBUT, non-invasive tear break-up time; OR, ocular redness.
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of view, the initial condition of N-Ws was already that of
healthy and young subjects and the AT effect, although
statistically significant, is clinically less important. More
interesting is the significant AT effect on the OR of DD-
Ws, considering their initial worse condition. The same
cannot be said for the OR of BW-Ws. Their initial condi-
tion was also worse than in N-Ws, but no significant
improvement was seen with the use of ATs.
The other parameter that showed a statistically signifi-
cant variation in DD-Ws was DEQ-5 (−34%). Also in this
case, the improvement was not significant in BW-Ws,
while it was significant for N-Ws (−21%), but less relevant
from the clinical point of view, their initial condition being
already fully compatible with that of young and healthy
subjects. For all three groups, no significant variation was
found for tear volume (TMH). Concerning tear stability,
the mean NIBUT was higher after 15 days in all 3 groups
(+26%, +51%, and +35%), but the difference was statisti-
cally significant only for BW-Ws.
As such, the main finding of this study is the general
significant improvement of the external eye comfort and
condition (DEQ5 and OR in Table 3) evaluated after
15 days of use of the ATs under investigation in N-Ws
and in DD-Ws, without any significant change of the TMH
(Table 3). This indicates that the aqueous-supplementing
effect of the AT is more a rinsing and tear replacement
effect than an increase in tear volume. Not having found
significant differences between the two ATs (Table 3 and
mean data shown in Figure 2) represents a further con-
firmation of a positive effect mainly due to simple rinsing
and tear replacement, as OPTOidro is a simple saline
solution. This work concerns young and healthy subjects.
In other studies reported in the literature, differences
between different ATs were found when applied to dry
eye subjects. The highest viscosity ATs were found to be
preferable to treat these cases.12,13,22,27 In patients with
deficient lipid layers, lipid emulsion eyedrops were also
found to produce positive effects.23,25
Rinsing and replacement of tear film were not enough
to produce any clear and statistically significant OR and
comfort benefit in the case of 1-month replacement CLs of
the same material used during the day for 8±1 hours a day
for 2 weeks (BW-Ws). This can be due to various reasons.
It must be said that the care system used in this work is the
same as that used in a previous study29 in which monthly
comfilcon A silicone-hydrogels CLs were used for
15 days. In that study, the external-eye condition of CL
wearers was evaluated before and after 15 days of dailyT
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wear combined with different care systems: hydrogen per-
oxide such as in the present work (first group in
Moro et al29), detergent solution combined with hydrogen
peroxide (second group in Moro et al29), and multipurpose
solution (third group in Moro et al29). That study was
aimed at comparing the different maintenance systems.
A worsening of the external-eye condition was reported
only in the first group, which can be attributed to a lower
cleaning efficacy of the hydrogen peroxide compared to
the other two care systems or to a different effect on the
CL wettability, surface friction, or on other CL properties.
The present study highlights that the use of the ATs under
investigation at least prevents the worsening after 2 weeks
of wear of the monthly CLs treated with hydrogen per-
oxide. Unfortunately, ATs did not significantly improve the
symptoms and ocular signs in BW-Ws.
An extension of this work could be the study of the effects
of OPTOyalA and OPTOidro ATs in wearers of other types of
CLs of different materials, also with the aim to shed more
light on the reason why the effectiveness of ATs was not
found in the case of BW-Ws. The study could also include
chemical-physical analysis of the CLs used together with the
ATs, eg, surface wettability and friction measurements,47,48
surface morphology and elemental characterization.49,50
Conclusions
On young and healthy CL wearers, the aqueous-
supplementing effect of the ATs under consideration was
mainly a rinsing and tear replacement effect, which
allowed an improvement of the ocular redness and eye
comfort, without any significant increase in tear volume
after 2 weeks of use. The efficacy of the ATs appeared to
be correlated with the replacement schedule of the lenses.
There was a less significant improvement in monthly
replacement CL wearers compared with daily disposable
CL wearers. Nonetheless, ATs appeared to prevent the
worsening of the external eye condition that was pre-
viously reported after 2 weeks of silicone-hydrogel CL
wear combined with hydrogen peroxide cleaning system.
The efficacy of the ATs was observed also in the control
group (non-wearers), although it is less relevant from the
clinical point of view, given their initial condition of
young and healthy subjects.
Disclosure
The authors report no conflicts of interest in this work.
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